List of Colcrys drug patents

Colcrys is owned by Takeda Pharms Usa.

Colcrys contains Colchicine.

Colcrys has a total of 17 drug patents out of which 0 drug patents have expired.

Colcrys was authorised for market use on 29 July, 2009.

Colcrys is available in tablet;oral dosage forms.

Colcrys can be used as method of treating gout flares, for the treatment and prophylaxis of gout flares & the treatment of familial mediterranean fever, method of administering colchicine to familial mediterranean fever patients, method of using colchicine for the prophylaxis of gout flares, a method for treatment of gout flares during prophylaxis.

The generics of Colcrys are possible to be released after 17 February, 2029.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8093296 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and macrolide antibiotics
Oct, 2028

(5 years from now)

US7964648 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and a second active agent
Oct, 2028

(5 years from now)

US7981938 TAKEDA PHARMS USA Colchicine compositions and methods
Oct, 2028

(5 years from now)

US7964647 TAKEDA PHARMS USA Colchicine compositions and methods
Oct, 2028

(5 years from now)

US8093297 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and a second active agent
Oct, 2028

(5 years from now)

US8097655 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and macrolide antibiotics
Oct, 2028

(5 years from now)

US8415396 TAKEDA PHARMS USA Colchine compositions and methods
Oct, 2028

(5 years from now)

US8415395 TAKEDA PHARMS USA Colchicine compositions and methods
Oct, 2028

(5 years from now)

US8093298 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and macrolide antibiotics
Oct, 2028

(5 years from now)

US7619004 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and macrolide antibiotics
Dec, 2028

(5 years from now)

US7935731 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and macrolide antibiotics
Dec, 2028

(5 years from now)

US7601758 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and macrolide antibiotics in the treatment of gout flares
Feb, 2029

(6 years from now)

US7906519 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and a second active agent
Feb, 2029

(6 years from now)

US8440722 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and a second active agent
Feb, 2029

(6 years from now)

US8440721 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and a second active agent
Feb, 2029

(6 years from now)

US7915269 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and a second active agent
Feb, 2029

(6 years from now)

US7820681 TAKEDA PHARMS USA Methods for concomitant administration of colchicine and a second active agent
Feb, 2029

(6 years from now)

Drugs and Companies using COLCHICINE ingredient

Market Authorisation Date: 29 July, 2009

Treatment: Method of treating gout flares; For the treatment and prophylaxis of gout flares & the treatment of familial mediterranean fever; A method for treatment of gout flares during prophylaxis; Method of using colchicine for the prophylaxis of gout flares; Method of administering colchicine to familial mediterranean fever patients

Dosage: TABLET;ORAL

How can I launch a generic of COLCRYS before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in